Evaluation of Organized Human Papilloma Virus (HPV) Screening of 23-29-year-old Women

What this Trial Is About

Researchers are investigating whether primary HPV analysis in organized cervical screening offers better protection against cervical cancer for women aged 23 to 29 compared to the current primary cytology method. This study includes all women in this age group living in the Stockholm and Skåne regions of Sweden, with sampling and sample collection methods remaining the same as those used for cytology. Women invited to cervical screening will have their samples analyzed for HPV using the same procedures and accredited HPV screening platforms currently used for women aged 30 and above. The invitation process matches that used for older age groups, with clear information about opting out and data collection for quality evaluation. The cytology method used is liquid-based cytology. Throughout the study, researchers will monitor the incidence of cervical cancer yearly over a ten-year period. They will also assess the cost-effectiveness of the HPV screening method each year during this time. Study participants will undergo regular screening, with sample collection identical to current practices, and data will be collected for regional and national quality registers to evaluate care quality.

HPV-based Screening Among Women 23-29 Years of Age